Novel therapeutic uses and formulations of botulinum neurotoxins: a patent review (2012 – 2014)

Bibliography

• Byrne MP, Smith LA. Development of vaccines for prevention of botulism. Biochimie 2000;82(9-10):955-66
   PubMed Web of Science ®Google Scholar
• Meunier FA, Lisk G, Sesardic D, Dolly JO. Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol Cell Neurosci 2003;22(4):454-66
   PubMed Web of Science ®Google Scholar
• Abrams SB, Hallett M. Clinical utility of different botulinum neurotoxin preparations. Toxicon 2013;67:81-6
   PubMed Web of Science ®Google Scholar
• Stone HF, Zhu Z, Thach TQ, Ruegg CL. Characterization of diffusion and duration of action of a new botulinum toxin type A formulation. Toxicon 2011;58(2):159-67
   PubMed Web of Science ®Google Scholar
• Duggan MJ, Quinn CP, Chaddock JA, et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 2002;277(38):34846-52
   PubMed Web of Science ®Google Scholar
• Foster KA. The analgesic potential of clostridial neurotoxin derivatives. Expert Opin Investig Drugs 2004;13(11):1437-43
   PubMed Web of Science ®Google Scholar
• Keith F, John C. Targeted secretion inhibitors-innovative protein therapeutics. Toxins 2010;2(12):2795-815
   PubMed Web of Science ®Google Scholar
• Pickett A. Immunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristics. BioDrugs 2013;27(1):83-4
   PubMed Web of Science ®Google Scholar
• He C, Kim SW, Lee DS. In situ gelling stimuli-sensitive block copolymer hydrogels for drug delivery. J Control Release 2008;127(3):189-207
   PubMed Web of Science ®Google Scholar
• Matanovic MR, Kristl J, Grabnar PA. Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications. Int J Pharm 2014;472(1-2):262-75
   PubMed Web of Science ®Google Scholar
• Nguyen MK, Lee DS. Injectable biodegradable hydrogels. Macromol Biosci 2010;10(6):563-79
   PubMed Web of Science ®Google Scholar
• Theracoat Ltd. Reverse thermal hydrogel preparations for the use in the treatment of disorders of the urothelium. WO153550; 2013
   Google Scholar
• Mangera A, Andersson KE, Apostolidis A, et al. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol 2011;60(4):784-95
   PubMed Web of Science ®Google Scholar
• Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol 2014;65(5):981-90
   PubMed Web of Science ®Google Scholar
• Michel MC. OnabotulinumtoxinA: how deep will it go? Eur Urol 2014;65(6):1125-7
   PubMed Web of Science ®Google Scholar
• Botox [Package Insert]. Allergan, Inc; Irvine, CA: 2013
   Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin A administration inhibits COX-2 and EP4 expression and suppresses bladder hyperactivity in cyclophosphamide-induced cystitis in rats. Eur Urol 2009;56(1):159-66
   PubMed Web of Science ®Google Scholar
• Eldrup J, Thorup J, Nielsen SL, et al. Permeability and ultrastructure of human bladder epithelium. Br J Urol 1983;55(5):488-92
   PubMedGoogle Scholar
• Parsons CL, Boychuk D, Jones S, et al. Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol 1990;143(1):139-42
   PubMed Web of Science ®Google Scholar
• Tyagi P, Kashyap MP, Kawamorita N, et al. Intravesical liposome and antisense treatment for detrusor overactivity and interstitial cystitis/painful bladder syndrome. ISRN Pharmacol 2014;2014:601653
   PubMedGoogle Scholar
• Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol 2012;61(6):1178-84
   PubMed Web of Science ®Google Scholar
• Krhut J, Zvara P. Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int Urol Nephrol 2011;43(2):337-43
   PubMed Web of Science ®Google Scholar
• van Uhm JI, Beckers GM, van der Laarse WJ, et al. Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle strips. BMC Urol 2014;14:37
   PubMed Web of Science ®Google Scholar
• NCT01997983. Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01997983
   Google Scholar
• NCT02179099. Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02179099
   Google Scholar
• McNeil SE. Nanotechnology for the biologist. J Leukoc Biol 2005;78(3):585-94
   PubMed Web of Science ®Google Scholar
• Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov 2014;13(9):655-72
   PubMed Web of Science ®Google Scholar
• Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 2010;9(8):615-27
   PubMed Web of Science ®Google Scholar
• Barenholz Y. Doxil(R) – the first FDA-approved nano-drug: lessons learned. J Control Release 2012;160(2):117-34
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang CC, et al. Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol 2009;182(2):786-92
   PubMed Web of Science ®Google Scholar
• Lipella Pharmaceuticals, Inc. Method of treatment for bladder dysfunction. WO139984; 2009
   Google Scholar
• Chapple C, Patel A. Botulinum toxin – new mechanisms, new therapeutic directions? Eur Urol 2006;49(4):606-8
   PubMed Web of Science ®Google Scholar
• Chuang YC, Yoshimura N, Huang CC, et al. Intravesical botulinum toxin a administration produces analgesia against acetic acid induced bladder pain responses in rats. J Urol 2004;172(4 Pt 1):1529-32
   PubMed Web of Science ®Google Scholar
• Chapple C, Sievert KD, MacDiarmid S, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64(2):249-56
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liu HT, Chuang YC, et al. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol 2014;65(6):1117-24
   PubMed Web of Science ®Google Scholar
• Kuo HC, Liao CH, Chung SD. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome. Eur Urol 2010;58(6):919-26
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177(6):2231-6
   PubMed Web of Science ®Google Scholar
• Lipella Pharmaceuticals, Inc. Methods and compositions for treating gastric disorders. WO116822; 2013
   Google Scholar
• Stavropoulos SN, Friedel D, Modayil R, et al. Endoscopic approaches to treatment of achalasia. Therap Adv Gastroenterol 2013;6(2):115-35
   PubMed Web of Science ®Google Scholar
• Bashashati M, Andrews C, Ghosh S, Storr M. Botulinum toxin in the treatment of diffuse esophageal spasm. Dis Esophagus 2010;23(7):554-60
   PubMed Web of Science ®Google Scholar
• Kroupa R, Hep A, Dolina J, et al. Combined treatment of achalasia - botulinum toxin injection followed by pneumatic dilatation: long-term results. Dis Esophagus 2010;23(2):100-5
   PubMed Web of Science ®Google Scholar
• Ramzan Z, Nassri AB. The role of Botulinum toxin injection in the management of achalasia. Curr Opin Gastroenterol 2013;29(4):468-73
   PubMed Web of Science ®Google Scholar
• Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324(17):1186-94
   PubMed Web of Science ®Google Scholar
• Wisconsin Alumni Research Foundation. Purification, characterization, and use of clostridium botulinum neurotoxin BoNT/A3. WO2013049139; 2013
   Google Scholar
• Hill KK, Smith TJ. Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes. Curr Top Microbiol Immunol 2013;364:1-20
   PubMed Web of Science ®Google Scholar
• Kull S, Schulz KM, Strotmeier JW, et al. Isolation and functional characterization of the novel clostridium botulinum neurotoxin A8 subtype. PLoS One 2015;10(2):e0116381
   PubMed Web of Science ®Google Scholar
• Arndt JW, Jacobson MJ, Abola EE, et al. A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol 2006;362(4):733-42
   PubMed Web of Science ®Google Scholar
• Webb RP, Smith TJ, Wright P, et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine 2009;27(33):4490-7
   PubMed Web of Science ®Google Scholar
• Tepp WH, Lin G, Johnson EA. Purification and characterization of a novel subtype a3 botulinum neurotoxin. Appl Environ Microbiol 2012;78(9):3108-13
   PubMed Web of Science ®Google Scholar
• Whitemarsh RC, Tepp WH, Bradshaw M, et al. Characterization of botulinum neurotoxin A subtypes 1 through 5 by investigation of activities in mice, in neuronal cell cultures, and in vitro. Infect Immun 2013;81(10):3894-902
   PubMed Web of Science ®Google Scholar
• Whitemarsh RC, Tepp WH, Johnson EA, Pellett S. Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells. PLoS One 2014;9(2):e90252
   PubMed Web of Science ®Google Scholar
• Mazuet C, Dano J, Popoff MR, et al. Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity. PLoS One 2010;5(8):e12416
   PubMed Web of Science ®Google Scholar
• Atassi MZ, Dolimbek BZ, Steward LE, Aoki KR. Molecular bases of protective immune responses against botulinum neurotoxin A – how antitoxin antibodies block its action. Crit Rev Immunol 2007;27(4):319-41
   PubMed Web of Science ®Google Scholar
• Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain 2002;18(6 Suppl):S133-41
   PubMed Web of Science ®Google Scholar
• Lange O, Bigalke H, Dengler R, et al. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol 2009;32(4):213-18
   PubMed Web of Science ®Google Scholar
• Hefter H, Spiess C, Rosenthal D. Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis. J Neural Transm 2014;121(5):513-19
   PubMed Web of Science ®Google Scholar
• Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm 2013;120(2):275-90
   PubMed Web of Science ®Google Scholar
• Dysport [Package Insert]. Ipsen Biopharm Ltd; 2009
   Google Scholar
• Myobloc [Package Insert]. Solstice Neurosciences, Inc; 2009
   Google Scholar
• Xeomin [Package Insert]. Merz Pharmaceuticals, LLC; 2011
   Google Scholar
• Brin MF, Dressler D, Aoki KR. Pharmacology of botulinum toxin therapy. In: Dystonia: etiology, clinical features, and treatment. Williams & Wilkins; Philadelphia, PA: 2004
   Google Scholar
• Chen C, Wang S, Wang H, et al. Potent neutralization of botulinum neurotoxin/B by synergistic action of antibodies recognizing protein and ganglioside receptor binding domain. PLoS One 2012;7(8):e43845
   PubMed Web of Science ®Google Scholar
• Mukherjee J, Tremblay JM, Leysath CE, et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 2012;7(1):e29941
   PubMed Web of Science ®Google Scholar
• Syntaxin Ltd. & Ipsen Biopharm Ltd. Recombinant clostridium botulinum neurotoxins. WO068317; 2014
   Google Scholar
• Eleopra R, Tugnoli V, Rossetto O, et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 1998;256(3):135-8
   PubMed Web of Science ®Google Scholar
• Sloop RR, Cole BA, Escutin RO. Human response to botulinum toxin injection: type B compared with type A. Neurology 1997;49(1):189-94
   PubMed Web of Science ®Google Scholar
• Foran PG, Mohammed N, Lisk GO, et al. Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J Biol Chem 2003;278(2):1363-71
   PubMed Web of Science ®Google Scholar
• Tsai YC, Maditz R, Kuo CL, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA 2010;107(38):16554-9
   PubMed Web of Science ®Google Scholar
• Merz Pharm Gmbh & Co. KGaA. Clostridial neurotoxins for use in tissue healing. WO035225; 2006
   Google Scholar
• Angov E. Codon usage: nature’s roadmap to expression and folding of proteins. Biotechnol J 2011;6(6):650-9
   PubMed Web of Science ®Google Scholar
• Dolly JO, Wang J, Zurawski TH, Meng J. Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J 2011;278(23):4454-66
   PubMed Web of Science ®Google Scholar
• Wang J, Meng J, Lawrence GW, et al. Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics. J Biol Chem 2008;283(25):16993-7002
   PubMed Web of Science ®Google Scholar
• Chinnapongse RB, Lew MF, Ferreira JJ, et al. Immunogenicity and long-term efficacy of botulinum toxin type B in the treatment of cervical dystonia: report of 4 prospective, multicenter trials. Clin Neuropharmacol 2012;35(5):215-23
   PubMed Web of Science ®Google Scholar
• President and Fellows of Harvard College. Engineered botulinum neurotoxin. WO180799; 2013
   Google Scholar
• Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986;103(2):521-34
   PubMed Web of Science ®Google Scholar
• Dolly JO, Black J, Williams RS, Melling J. Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization. Nature 1984;307(5950):457-60
   PubMed Web of Science ®Google Scholar
• Dong M, Richards DA, Goodnough MC, et al. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J Cell Biol 2003;162(7):1293-303
   PubMed Web of Science ®Google Scholar
• Nishiki T, Kamata Y, Nemoto Y, et al. Identification of protein receptor for Clostridium botulinum type B neurotoxin in rat brain synaptosomes. J Biol Chem 1994;269(14):10498-503
   PubMed Web of Science ®Google Scholar
• Rummel A, Karnath T, Henke T, et al. Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. J Biol Chem 2004;279(29):30865-70
   PubMed Web of Science ®Google Scholar
• Peng L, Berntsson RP, Tepp WH, et al. Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins. J Cell Sci 2012;125(Pt 13):3233-42
   PubMed Web of Science ®Google Scholar
• Strotmeier J, Willjes G, Binz T, Rummel A. Human synaptotagmin-II is not a high affinity receptor for botulinum neurotoxin B and G: increased therapeutic dosage and immunogenicity. FEBS Lett 2012;586(4):310-13
   PubMed Web of Science ®Google Scholar
• Chai Q, Arndt JW, Dong M, et al. Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature 2006;444(7122):1096-100
   PubMed Web of Science ®Google Scholar
• Jin R, Rummel A, Binz T, Brunger AT. Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity. Nature 2006;444(7122):1092-5
   PubMed Web of Science ®Google Scholar
• Rummel A, Mahrhold S, Bigalke H, Binz T. Exchange of the H(CC) domain mediating double receptor recognition improves the pharmacodynamic properties of botulinum neurotoxin. FEBS J 2011;278(23):4506-15
   PubMed Web of Science ®Google Scholar
• Syntaxin Ltd. Fusion proteins and methods for treating, preventing, or ameliorating pain. WO033441; 2014
   Google Scholar
• Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30(7):793-803
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30(7):804-14
   PubMed Web of Science ®Google Scholar
• Brin MF, Fahn S, Moskowitz C, et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 1987;2(4):237-54
   PubMed Web of Science ®Google Scholar
• Dolly JO, Lawrence GW, Meng J, et al. Neuro-exocytosis: botulinum toxins as inhibitory probes and versatile therapeutics. Curr Opin Pharmacol 2009;9(3):326-35
   PubMed Web of Science ®Google Scholar
• Ramachandran R, Yaksh TL. Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 2014;171(18):4177-92
   PubMed Web of Science ®Google Scholar
• Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. Parkinsonism Relat Disord 2011;17(Suppl 1):S28-33
   PubMed Web of Science ®Google Scholar
• Dolly JO, O’Connell MA. Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol 2012;12(1):100-8
   PubMed Web of Science ®Google Scholar
• Wheeler A, Smith HS. Botulinum toxins: mechanisms of action, antinociception and clinical applications. Toxicology 2013;306:124-46
   PubMed Web of Science ®Google Scholar
• Health Protection Agency (Great Britain) and Allergan, Inc. Fusion Proteins. WO059093; 2006
   Google Scholar
• Xu XJ, Hokfelt T, Bartfai T, Wiesenfeld-Hallin Z. Galanin and spinal nociceptive mechanisms: recent advances and therapeutic implications. Neuropeptides 2000;34(3-4):137-47
   PubMed Web of Science ®Google Scholar
• Borowsky B, Walker MW, Huang LY, et al. Cloning and characterization of the human galanin GALR2 receptor. Peptides 1998;19(10):1771-81
   PubMed Web of Science ®Google Scholar
• Liu HX, Hokfelt T. The participation of galanin in pain processing at the spinal level. Trends Pharmacol Sci 2002;23(10):468-74
   PubMed Web of Science ®Google Scholar
• Mitsukawa K, Lu X, Bartfai T. Galanin, galanin receptors and drug targets. Cell Mol Life Sci 2008;65(12):1796-805
   PubMed Web of Science ®Google Scholar
• Masuyer G, Chaddock JA, Foster KA, Acharya KR. Engineered botulinum neurotoxins as new therapeutics. Annu Rev Pharmacol Toxicol 2014;54:27-51
   PubMed Web of Science ®Google Scholar
• NCT01678924. A Safety and Efficacy Study of AGN-214868 in Patients With Postherpetic Neuralgia. Available from: https://clinicaltrials.gov/ct2/show/NCT01678924
   Google Scholar
• Singh BR. Botulinum chimera compositions for axonal regenerative therapy during spinal cord injury. WO113539; 2014
   Google Scholar
• Thuret S, Moon LD, Gage FH. Therapeutic interventions after spinal cord injury. Nat Rev Neurosci 2006;7(8):628-43
   PubMed Web of Science ®Google Scholar
• McKerracher L, Guertin P. Rho as a target to promote repair: translation to clinical studies with Cethrin. Curr Pharm Des 2013;19(24):4400-10
   PubMed Web of Science ®Google Scholar
• Lu Q, Longo FM, Zhou H, et al. Signaling through Rho GTPase pathway as viable drug target. Curr Med Chem 2009;16(11):1355-65
   PubMed Web of Science ®Google Scholar
• Lehmann M, Fournier A, Selles-Navarro I, et al. Inactivation of Rho signaling pathway promotes CNS axon regeneration. J Neurosci 1999;19(17):7537-47
   PubMed Web of Science ®Google Scholar
• Winton MJ, Dubreuil CI, Lasko D, et al. Characterization of new cell permeable C3-like proteins that inactivate Rho and stimulate neurite outgrowth on inhibitory substrates. J Biol Chem 2002;277(36):32820-9
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Theodore N, Harrop J, et al. A phase I/IIa clinical trial of a recombinant Rho protein antagonist in acute spinal cord injury. J Neurotrauma 2011;28(5):787-96
   PubMed Web of Science ®Google Scholar
• McKerracher L, Anderson KD. Analysis of recruitment and outcomes in the phase I/IIa Cethrin clinical trial for acute spinal cord injury. J Neurotrauma 2013;30(21):1795-804
   PubMed Web of Science ®Google Scholar
• Holtje M, Djalali S, Hofmann F, et al. A 29-amino acid fragment of Clostridium botulinum C3 protein enhances neuronal outgrowth, connectivity, and reinnervation. FASEB J 2009;23(4):1115-26
   PubMed Web of Science ®Google Scholar
• Huelsenbeck SC, Rohrbeck A, Handreck A, et al. C3 peptide promotes axonal regeneration and functional motor recovery after peripheral nerve injury. Neurotherapeutics 2012;9(1):185-98
   PubMed Web of Science ®Google Scholar
• Loske P, Boato F, Hendrix S, et al. Minimal essential length of Clostridium botulinum C3 peptides to enhance neuronal regenerative growth and connectivity in a non-enzymatic mode. J Neurochem 2012;120(6):1084-96
   PubMed Web of Science ®Google Scholar
• Just I, Hofmann F, Ahnert-Hilger G, Grosse G. Enzyme-Deficient C3 botulinum protein species and their use to promote neuronal growth and neuronal regeneration. WO037920;2003
   Google Scholar
• Wang J, Zurawski TH, Meng J, et al. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic. J Biol Chem 2011;286(8):6375-85
   PubMed Web of Science ®Google Scholar
• O’Leary VB, Ovsepian SV, Raghunath A, et al. Innocuous full-length botulinum neurotoxin targets and promotes the expression of lentiviral vectors in central and autonomic neurons. Gene Ther 2011;18(7):656-65
   PubMed Web of Science ®Google Scholar
• Edupuganti OP, Ovsepian SV, Wang J, et al. Targeted delivery into motor nerve terminals of inhibitors for SNARE-cleaving proteases via liposomes coupled to an atoxic botulinum neurotoxin. FEBS J 2012;279(14):2555-67
   PubMed Web of Science ®Google Scholar
• Kukreja RV, Sharma S, Cai S, Singh BR. Role of two active site Glu residues in the molecular action of botulinum neurotoxin endopeptidase. Biochim Biophys Acta 2007;1774(2):213-22
   PubMed Web of Science ®Google Scholar
• Yang W, Lindo P, Riding S, et al. Expression, purification, and comparative characterization of enzymatically deactivated recombinant botulinum neurotoxin type A. The Botulinum J2008;1(2):219-41
   Google Scholar
• Baskaran P, Lehmann TE, Topchiy E, et al. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions. Toxicon 2013;72:71-80
   PubMed Web of Science ®Google Scholar
• Naumann M, So Y, Argoff CE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70(19):1707-14
   PubMed Web of Science ®Google Scholar
• Brin MF, Boodhoo TI, Pogoda JM, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol 2009;61(6):961-70; e1-11
   PubMed Web of Science ®Google Scholar
• Allergan, Inc. Prophylactic treatment of herpes recurrence. WO100019; 2014
   Google Scholar
• Garcia EA, Trivellin G, Aflorei ED, et al. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly? J Clin Endocrinol Metab 2013;98(12):E1918-26
   PubMed Web of Science ®Google Scholar
• Somm E, Bonnet N, Martinez A, et al. A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest 2012;122(9):3295-306
   PubMed Web of Science ®Google Scholar
• Allergan Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases. WO112434; 2012
   Google Scholar
• Frevert J. Content of botulinum neurotoxin in Botox(R)/Vistabel(R), Dysport(R)/Azzalure(R), and Xeomin(R)/Bocouture(R). Drugs R D 2010;10(2):67-73
   PubMedGoogle Scholar
• Simpson L. The life history of a botulinum toxin molecule. Toxicon 2013;68:40-59
   PubMed Web of Science ®Google Scholar
• Brunger AT, Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon 2009;54(5):550-60
   PubMed Web of Science ®Google Scholar
• Rummel A, Eichner T, Weil T, et al. Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept. Proc Natl Acad Sci USA 2007;104(1):359-64
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, et al. SV2 is the protein receptor for botulinum neurotoxin A. Science 2006;312(5773):592-6
   PubMed Web of Science ®Google Scholar
• Mahrhold S, Rummel A, Bigalke H, et al. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBS Lett 2006;580(8):2011-14
   PubMed Web of Science ®Google Scholar
• Binz T, Blasi J, Yamasaki S, et al. Proteolysis of SNAP-25 by types E and A botulinal neurotoxins. J Biol Chem 1994;269(3):1617-20
   PubMed Web of Science ®Google Scholar
• Schiavo G, Malizio C, Trimble WS, et al. Botulinum G neurotoxin cleaves VAMP/synaptobrevin at a single Ala-Ala peptide bond. J Biol Chem 1994;269(32):20213-16
   PubMed Web of Science ®Google Scholar
• Schiavo G, Rossetto O, Catsicas S, et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E. J Biol Chem 1993;268(32):23784-7
   PubMed Web of Science ®Google Scholar
• Schiavo G, Rossetto O, Santucci A, et al. Botulinum neurotoxins are zinc proteins. J Biol Chem 1992;267(33):23479-83
   PubMed Web of Science ®Google Scholar
• Schiavo G, Shone CC, Rossetto O, et al. Botulinum neurotoxin serotype F is a zinc endopeptidase specific for VAMP/synaptobrevin. J Biol Chem 1993;268(16):11516-19
   PubMed Web of Science ®Google Scholar
• Foran P, Lawrence GW, Shone CC, et al. Botulinum neurotoxin C1 cleaves both Syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 1996;35(8):2630-6
   PubMed Web of Science ®Google Scholar
• Benefield DA, Dessain SK, Shine N, et al. Molecular assembly of botulinum neurotoxin progenitor complexes. Proc Natl Acad Sci USA 2013;110(14):5630-5
   PubMed Web of Science ®Google Scholar
• Lee K, Gu S, Jin L, et al. Structure of a bimodular botulinum neurotoxin complex provides insights into its oral toxicity. PLoS Pathog 2013;9(10):e1003690
   PubMed Web of Science ®Google Scholar